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Abstract
Objectives
To determine the prevalence of polypharmacy prescription among type 2 diabetes (T2DM)
patients at a tertiary care department in Ningbo, China, and to determine factors that inde-
pendently predict this polypharmacy prescription.
Methods
A retrospective cross-sectional study was conducted using an existing computerised medi-
cal records database. This database was screened from 2012 to 2017 for adult patients with
T2DM and parameters like prescribed medicines and socio-demographic, behavioural and
other medical information. Polypharmacy prescription was defined as the simultaneous pre-
scription of�5 medicines by the clinician at the time of discharge for daily usage by the
patient as part of his/her long-term treatment plan.
Results
The study inclusion criteria were satisfied by 3370 T2DM patients. Over a 5-year period,
72.2% (n = 2432) of T2DM patients were prescribed polypharmacy. On an average, eight
medicines were prescribed to them. The odds of polypharmacy prescription increased with
patients’ age (18–39 years: 1; 40–59 years: OR 1.86, 95% CI 1.28–2.71; and�60 years:
2.42, 1.65–3.55), duration of T2DM (�1 year: 1; >5–10 years: 1.70, 1.10–2.62; and >10
years: 2.55, 1.68–3.89), and length of hospital stay (�5 days: 1; >5–10 days: 2.43, 1.86–
3.17; and >10 days: 2.99, 2.24–3.99), and were higher in those with poor blood glucose
level (2.09, 1.67–2.62) and with comorbidities like other endocrine, nutritional and metabolic
diseases (2.24, 1.76–2.85), circulatory system diseases (4.35, 3.62–5.23), skin and subcu-
taneous tissue diseases (1.64, 1.04–2.59), and musculoskeletal system and connective tis-
sue diseases (1.61, 1.27–2.03). The odds of polypharmacy prescription were lower in those
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with comorbidities like neoplasms (0.51, 0.36–0.70) and during pregnancy, childbirth and
the puerperium (0.06, 0.01–0.49).
Conclusions
Around three fourth of T2DM patients at the tertiary care department were prescribed poly-
pharmacy, and the predictors were identified. The study findings could be taken into consid-
eration in future interventional studies aimed at supporting medicines optimisation (and
deprescribing) among these patients.
Introduction
Type 2 diabetes (T2DM), a complex metabolic disorder, has major health, social and economic
consequences. Globally, China has the largest T2DM epidemic. Currently, around 114 million
(11%) adults are living with T2DM, which is expected to rise to 120 million by 2045 [1].
Ningbo, an economically developed city, is located in the northeast Zhejiang province of
China. In 2015, the T2DM prevalence in adults over 40 years of age in Ningbo was 21% [2]. At
a tertiary care department (Department of Endocrinology and Metabolism, Ningbo First Hos-
pital), more than 50% of T2DM patients receiving treatment had poor glycaemic control and
vascular complications [3]. The study was conducted at Ningbo First Hospital. This is a tertiary
care hospital (with 1600 beds), which is primarily responsible for delivering specialist health
services and for performing a larger role in medical education and research [4,5]. Nationals
(including T2DM patients) can visit any Chinese hospital of their choice and is not based on a
referral system by the general practitioners. Thus, this hospital is visited by local people, as well
as those from surrounding areas [4].
The concurrent prescription or usage of multiple medicines is known as polypharmacy [6].
Polypharmacy can lead to interactions between drugs and results in adverse drug events [7–9].
It can have a negative effect on the T2DM patient, their family/carer, the health system and the
economy. In patients, it can adversely affect their adherence to medicines, quality of life and
life expectancy, can lead to suboptimal blood glucose control and hospital admissions, and can
increase severe hypoglycaemia risk and healthcare costs [10–14]. Studies conducted in differ-
ent diabetes (including T2DM) populations and settings have reported a range of polyphar-
macy prevalence figures (6–85%) [15–24].
Until now, no research has been conducted to explore polypharmacy prescription among
T2DM patients at this tertiary care department. The study objectives were to determine the
prevalence of polypharmacy prescription among T2DM patients at this tertiary care depart-
ment and to determine factors that independently predict this polypharmacy prescription. The
knowledge of the prevalence of polypharmacy prescription and factors associated with their
polypharmacy prescription could be used by Chinese and/or international experts in develop-
ing, evaluating and implementing interventions for supporting medicines optimisation (and
deprescribing) in Ningbo and beyond in China.
Materials and methods
Study design, data source and period
The 5-year study period was from 1 July 2012 to 30 June 2017. An existing computerised medi-
cal records database was used in conducting a retrospective cross-sectional study. The database
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includes information on all patients from their admission to discharge, including their socio-
demographic and behavioural information, medical and surgical history, diagnostics (includ-
ing laboratory results) and prescribed medicines. As this is a medical records database, the
medico-nursing team is responsible for data entry on to the database. Another independent
team of hospital staff checks the quality of the data and is responsible for the overall manage-
ment of the database. On our request and with permission from the Research Ethics Commit-
tee at the Ningbo First Hospital, China, the data were extracted from the database by a
dedicated engineer.
Study population, inclusion and exclusion criteria
The study included adult (�18 years of age) T2DM inpatients who were discharged from the
tertiary care department for the first time during the study period. If a patient had more than
one hospitalisation during the study period, only data relevant to the index event (ie, first hos-
pitalisation) were extracted. Although the database includes information on all inpatients from
their admission to discharge, we extracted the prescription data at the time of discharge, as
medicines were prescribed as part of their long-term treatment plan. The study excluded those
diagnosed with type 1 diabetes, secondary diabetes, gestational diabetes, unknown type of dia-
betes or endocrine diseases (such as hyperthyroidism and Cushing syndrome).
Study variables
We extracted the following independent variables from the database: age (18–39 years (younger
age), 40–59 years (middle age) or�60 years (older age)) [25], sex (male or female), education
(university/college, class 7–12, class 1–6 or no qualifications), occupation (manual workers (ie,
more physical than mental work), non-manual workers (ie, more mental than physical work) or
never worked/retired), marital status (married or single/divorced/widowed), residence (urban or
rural based on the “hukou” system (ie, residence registration system in China)) [26], health insur-
ance, smoking (current status), alcohol drinking (current status), duration of T2DM (�1 year,
>1–5 years,>5–10 years or>10 years), blood glucose level (glycated haemoglobin (HbA1c)—
<7% (good) or�7% (poor)) [27]; estimated using the high-performance liquid chromatographic
(HPLC) method, using the D-10 Hemoglobin Analyzer (Bio-Rad, USA)), length of hospital stay
(�5 days,>5–10 days or>10 days) and comorbidities (ie,�1 comorbidities and were coded
using the International Statistical Classification of Diseases, 10th revision (ICD-10)) [28]. The
dependent variable extracted was prescribed medicines at discharge, which were coded using the
World Health Organization’s Anatomical Therapeutic and Chemical (ATC) Classification [29]. A
polypill was counted as a single medicine. Polypharmacy prescription was defined as the simulta-
neous prescription of�5 medicines by the clinician at the time of discharge for daily usage by the
patient as part of his/her long-term treatment plan [17,30,31].
Ethics
Ethics approval was obtained from the Research Ethics Committee at the Ningbo First Hospi-
tal, China. The authors had no access to information that could identify individual participants
during data analysis. Therefore, as per the research ethics rules, no informed consent was
necessary.
Statistical analyses
Over a 5-year period, amongst T2DM patients, the prevalence of polypharmacy prescription
was calculated. Numbers and proportions were calculated for categorical variables. Means and
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standard deviations (SDs) were calculated for normally distributed continuous variables. Sim-
ple logistic regression method was used to explore the relationship between independent vari-
ables and polypharmacy prescription. To find any independent relationship, multiple logistic
regression models were developed using backward stepwise regression analyses and we
included all the independent variables. We also carried out sensitivity analyses–in multiple
logistic regression models, only those independent variables with a p-value of�0.20 in simple
logistic regressions were included. We calculated Odds ratios (ORs) and their respective 95%
confidence intervals (CIs). IBM SPSS Statistics Version 20.0 for Windows was used for data
analysis. In addition, we carried out logistic regression analyses to explore the association
between neoplasms (no, benign and malignant) and polypharmacy prescription.
Results
The study inclusion criteria were satisfied by 3370 T2DM patients. The mean (±SD) age of
T2DM patients was 62.9 (±13.8) years and around 51% (n = 1713) of them were male. Over a
5-year period, amongst T2DM patients, the prevalence of polypharmacy prescription was
72.2% (n = 2432). Fig 1 shows the number of medicines that were prescribed in our study.
Those who were prescribed polypharmacy, the mean (± SD) number of comorbidities and
medicines were 5 (±2) and 8 (±2), respectively.
Table 1 shows the most common medicines which were prescribed in our study. 96.7% of
T2DM patients were on antidiabetic agents (79.8% were on oral antidiabetic drugs and 74.8%
were on insulin), 36.9% were on antithrombotic agents and 69.5% were on lipid modifying
agents.
Table 2 shows the characteristics of T2DM patients with and without polypharmacy pre-
scription. The polypharmacy prescription was found to be associated with age, education,
occupation, residence, health insurance, duration of T2DM (>5 years), blood glucose level,
length of hospital stay and commodities like neoplasm, other endocrine, nutritional and meta-
bolic diseases, nervous system diseases, circulatory system diseases, skin and subcutaneous tis-
sue diseases, musculoskeletal system and connective tissue diseases, genitourinary system
diseases and during pregnancy, childbirth and the puerperium.
Table 3 shows the multiple backward stepwise logistic regression analyses–all the indepen-
dent variables were included. The odds of polypharmacy prescription increased with patients’
age (18–39 years: 1; 40–59 years: OR 1.86, 95% CI 1.28–2.71; and�60 years: 2.42, 1.65–3.55),
duration of T2DM (�1 year: 1;>5–10 years: 1.70, 1.10–2.62; and>10 years: 2.55, 1.68–3.89),
and length of hospital stay (�5 days: 1; >5–10 days: 2.43, 1.86–3.17; and>10 days: 2.99, 2.24–
3.99), and were higher in those with poor blood glucose level (2.09, 1.67–2.62) and with
comorbidities like other endocrine, nutritional and metabolic diseases (2.24, 1.76–2.85), circu-
latory system diseases (4.35, 3.62–5.23), skin and subcutaneous tissue diseases (1.64, 1.04–
2.59), and musculoskeletal system and connective tissue diseases (1.61, 1.27–2.03). The odds of
polypharmacy prescription were lower in those with comorbidities like neoplasms (0.51, 0.36–
0.70) and during pregnancy, childbirth and the puerperium (0.06, 0.01–0.49).
Table 4 shows the sensitivity analyses (multiple logistic regression models)—independent
variables with p�0.20 in simple logistic regressions were included. We found similar results in
the sensitivity analyses.
Discussion
In our study, around three fourth of T2DM patients were prescribed polypharmacy. Those
who were prescribed polypharmacy, the average number of medicines was eight. Globally,
similar studies have been conducted in different diabetes populations and settings, during
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different time periods, using similar or different case definitions of polypharmacy. The preva-
lence of polypharmacy (�5 medicines) among T2DM patients in Italy and Brazil was 57% and
85%, respectively [17,21]. In similar studies conducted among diabetes patients in Brazil and
Saudi Arabia, it was 57% and 78%, respectively [16,18]. 48% of patients with diabetes and
hypertension in Canada were prescribed�9 medicines [19]. The average number of medicines
prescribed to T2DM patients in India and Germany was five and 12, respectively [15,20]. A
standardised universally accepted definition of polypharmacy is not available. A recently pub-
lished systematic review reported that approximately half of the published studies defined
polypharmacy as administering�5 medicines to an individual. They found a huge variation in
the definition of polypharmacy used, which ranged from�2 medicines to�11 medicines [32].
Therefore, in our study, we selected the most commonly used definition of polypharmacy ie,
the simultaneous prescription of�5 medicines.
Fig 1. Number of prescribed medicines in our study.
https://doi.org/10.1371/journal.pone.0220047.g001
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In T2DM, the core management strategy is to control blood glucose and prevent or manage
vascular complications [27]. Similar to our study, in China, the management of uncontrolled
blood glucose levels and T2DM complications (if any) are often the two main reasons for hos-
pitalisation of T2DM patients [33]. During their stay at the hospital, the management strategy
can be different and may involve multiple essential medicines for treating complex and severe
conditions. We found that around 80% of T2DM patients were prescribed oral antidiabetic
drugs and a high proportion (75%) were prescribed insulin. In China, if the first line of treat-
ment (oral antidiabetic drugs) fails to control the blood glucose levels, insulin (premix or
basal) is recommended and sometimes in combination with oral antidiabetic drugs [34]. All
these increases the complexity of T2DM management and the burden of medicines. Drug-
Table 1. Most commonly prescribed medicines in our study.
Classification of medicines (based on ATC classification) Number of
T2DM patients
n(%)
Alimentary tract and metabolism (A) 3312(98.3)
Drugs used in diabetes (A10) 3258(96.7)
Blood glucose lowering drugs, excl. insulins (A10B) 2688(79.8)
Alpha glucosidase inhibitors (A10BF) 1948(57.8)
Biguanides (A10BA) 1651(49.0)
Repaglinide/nateglinide (A10BX02, A10BX03) 476(14.1)
Sulfonamides (A10BB) 286(8.5)
Thiazolidinediones (A10BG) 71(2.1)
Insulin and analogues (A10A) 2520(74.8)
Insulins and analogues for injection, intermediate/long-acting (A10AC, A10AE) 1841(54.6)
Insulins and analogues for injection, fast-acting
(A10AB)
1251(37.1)
Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
(A10AD)
672(19.9)
Drugs for acid related disorders (A02) 699(20.7)
Proton pump inhibitors (A02BC) 662(19.6)
Cardiovascular system (C) 2790(82.8)
Lipid modifying agents (C10) 2343(69.5)
HMG CoA reductase inhibitors (C10AA) 2174(64.5)
Atorvastatin and amlodipine (C10BX03) 49(1.5)
Agents acting on the renin-angiotensin-aldosterone system (C09) 1640(48.7)
Angiotensin II antagonists and calcium channel blockers (C09DB) 537(15.9)
Angiotensin II antagonists and diuretics (C09DA) 161(4.8)
Calcium channel blockers (C08) 483(14.3)
Beta blocking agents (C07) 386(11.5)
Diuretics (C03) 254(7.5)
Cardiac therapy (C01) 245(7.3)
Blood and blood forming organs (B) 1789(53.1)
Antithrombotic agents (B01) 1244(36.9)
Acetylsalicylic acid (B01AC06) 1030(30.6)
Nervous system (N) 385(11.4)
Musculoskeletal system (M) 283(8.4)
Anti-infectives for systemic use(J) 281(8.3)
Genitourinary system and sex hormones (G) 204(6.1)
Respiratory system (R) 151(4.5)
https://doi.org/10.1371/journal.pone.0220047.t001
Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0220047 July 17, 2019 6 / 16
Table 2. Characteristics of T2DM patients with and without polypharmacy prescription.
Total (3370) Polypharmacy
prescription
No (938)
n(%)
Polypharmacy
prescription
Yes (2432)
n(%)
Unadjusted OR (95%
CI)
Age (in years)
18–39 205 141(68.8) 64(31.2) 1
40–59 1043 393(37.7) 650(62.3) 3.64(2.64,5.02)
�60 2122 404(19.0) 1718(81.0) 9.37(6.84,12.83)
Sex
Male 1713 474(27.7) 1239(72.3) 1
Female 1657 464(28.0) 1193(72.0) 0.98(0.85,1.14)
Education
University/college 352 142(40.3) 210(59.7) 1
Class 7–12 1322 400(30.3) 922(69.7) 1.56(1.22,1.99)
Class 1–6 1144 270(23.6) 874(76.4) 2.19(1.70,2.82)
No qualifications 552 126(22.8) 426(77.2) 2.29(1.71,3.06)
Occupation
Manual workers 727 211(29.0) 516(71.0) 1
Non-manual workers 771 319(41.4) 452(58.6) 0.58(0.47,0.72)
Never worked/retired 1872 408(21.8) 1464(78.2) 1.47(1.21,1.78)
Marital status
Married 2895 822(28.4) 2073(71.6) 1
Single/divorced/widowed 475 116(24.4) 359(75.6) 1.23(0.98,1.54)
Residence
Urban 1988 506(25.5) 1482(74.5) 1
Rural 1382 432(31.3) 950(68.7) 0.75(0.65,0.87)
Health insurance
Yes 2882 749(26.0) 2133(74.0) 1
No 488 189(38.7) 299(61.3) 0.56(0.46,0.68)
Smoking (current status)
No 2713 756(27.9) 1957(72.1) 1
Yes 657 182(27.7) 475(72.3) 1.01(0.83,1.22)
Alcohol drinking (current status)
No 3005 845(28.1) 2160(71.9) 1
Yes 365 93(25.5) 272(74.5) 1.14(0.89,1.47)
Duration of T2DM (in years)
�1 140 66(47.1) 74(52.9) 1
>1–5 780 346(44.4) 434(55.6) 1.12(0.78,1.61)
>5–10 746 227(30.4) 519(69.6) 2.04(1.41,2.94)
>10 1704 299(17.5) 1405(82.5) 4.19(2.94,5.97)
Blood glucose level (HbA1c)
<7% 603 221(36.7) 382(63.3) 1
�7% 2678 684(25.5) 1994(74.5) 1.69(1.40,2.03)
Unknown 89 33(37.1) 56(62.9) 0.98(0.62,1.56)
Length of hospital stay (in days)
�5 374 201(53.7) 173(46.3) 1
>5–10 1815 502(27.7) 1313(72.3) 3.04(2.42,3.82)
>10 1181 235(19.9) 946(80.1) 4.68(3.65,6.00)
Comorbidities
(Continued)
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drug interactions can be categorised as pharmacodynamics or pharmacokinetics [35]. The risk
of a potential drug interaction increases from 13% for two drugs to 82% for�7 drugs [36]. For
Table 2. (Continued)
Total (3370) Polypharmacy
prescription
No (938)
n(%)
Polypharmacy
prescription
Yes (2432)
n(%)
Unadjusted OR (95%
CI)
Infectious and parasitic diseases (A00-B99)
No 3048 846(27.8) 2202(72.2) 1
Yes 322 92(28.6) 230(71.4) 0.96(0.75,1.24)
Neoplasms (C00-D48)
No 3157 844(26.7) 2313(73.3) 1
Yes 213 94(44.1) 119(55.9) 0.46(0.35,0.61)
Blood diseases and certain disorders involving the immune mechanism
(D50-D89)
No 3271 909(27.8) 2362(72.2) 1
Yes 99 29(29.3) 70(70.7) 0.93(0.60,1.44)
Endocrine, nutritional and metabolic diseases (E00-E90)�
No 449 220(49.0) 229(51.0) 1
Yes 2921 718(24.6) 2203(75.4) 2.95(2.41,3.61)
Mental and behavioural disorders (F00-F99)
No 3275 919(28.1) 2356(71.9) 1
Yes 95 19(20.0) 76(80.0) 1.56(0.94,2.59)
Nervous system diseases (G00-G99)
No 3159 895(28.3) 2264(71.7) 1
Yes 211 43(20.4) 168(79.6) 1.54(1.10,2.18)
Circulatory system diseases (I00-I99)
No 1210 608(50.2) 602(49.8) 1
Yes 2160 330(15.3) 1830(84.7) 5.60(4.76,6.59)
Respiratory system diseases (J00-J99)
No 2908 824(28.3) 2084(71.7) 1
Yes 462 114(24.7) 348(75.3) 1.21(0.96,1.51)
Digestive system diseases (K00-K93)
No 1800 510(28.3) 1290(71.7) 1
Yes 1570 428(27.3) 1142(72.7) 1.06(0.91,1.23)
Skin and subcutaneous tissue diseases (L00-L99)
No 3214 909(28.3) 2305(71.7) 1
Yes 156 29(18.6) 127(81.4) 1.73(1.15,2.60)
Musculoskeletal system and connective tissue diseases (M00-M99)
No 2639 807(30.6) 1832(69.4) 1
Yes 731 131(17.9) 600(82.1) 2.02(1.64,2.48)
Genitourinary system diseases (N00-N99)
No 2501 719(28.7) 1782(71.3) 1
Yes 869 219(25.2) 650(74.8) 1.20(1.01,1.43)
Pregnancy, childbirth and the puerperium (O00-O99)
No 3336 905(27.1) 2431(72.9) 1
Yes 34 33(97.1) 1(2.9) 0.01(0.00,0.08)
�Excludes T2DM
https://doi.org/10.1371/journal.pone.0220047.t002
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example, drugs like sulphonylurea and aspirin have a high tendency to bind with plasma
proteins [37,38]. When these two drugs are administered simultaneously, aspirin can com-
pete with sulphonylurea. Thereafter, aspirin can bind with plasma proteins, displacing
Table 3. Multiple backward stepwise logistic regression analyses to determine factors independently associated
with polypharmacy prescription—all the independent variables were included.
Adjusted OR (95% CI)
Polypharmacy prescription (Yes)
Age (in years)
18–39 1
40–59 1.86(1.28,2.71)
�60 2.42(1.65,3.55)
Duration of T2DM (in years)
�1 1
>1–5 1.23(0.81,1.88)
>5–10 1.70(1.10,2.62)
>10 2.55(1.68,3.89)
Length of hospital stay (in days)
�5 1
>5–10 2.43(1.86,3.17)
>10 2.99(2.24,3.99)
Blood glucose level (HbA1c)
<7% 1
�7% 2.09(1.67,2.62)
Unknown 1.19(0.69,2.06)
Neoplasms (C00-D48)
No 1
Yes 0.51(0.36,0.70)
Endocrine, nutritional and metabolic diseases (E00-E90)�
No 1
Yes 2.24(1.76,2.85)
Circulatory system diseases (I00-I99)
No 1
Yes 4.35(3.62,5.23)
Skin and subcutaneous tissue diseases (L00-L99)
No 1
Yes 1.64(1.04,2.59)
Musculoskeletal system and connective tissue diseases (M00-M99)
No 1
Yes 1.61(1.27,2.03)
Pregnancy, childbirth and the puerperium (O00-O99)
No 1
Yes 0.06(0.01,0.49)
�Excludes T2DM
Variables age, sex, education, occupation, marital status, residence, health insurance, smoking, alcohol drinking,
duration of T2DM, blood glucose level (HbA1c), length of hospital stay, infectious and parasitic diseases, neoplasms,
blood diseases, endocrine diseases, mental and behavioural disorders, nervous system diseases, circulatory system
diseases, respiratory system diseases, digestive system diseases, skin diseases, musculoskeletal system diseases,
genitourinary system diseases, pregnancy and the puerperium were included.
https://doi.org/10.1371/journal.pone.0220047.t003
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sulphonylurea from plasma proteins [38]. Due to this, the level of sulphonylurea in plasma can
increase, which in turn can increase the risk of hypoglycemia, especially among those T2DM
patients with controlled (near normal) blood glucose levels [39]. Almost two third of T2DM
Table 4. Sensitivity analyses (multiple logistic regression models)—independent variables with p�0.20 in simple
logistic regressions were included.
Adjusted OR (95% CI)
Polypharmacy prescription (Yes)
Age (in years)
18–39 1
40–59 1.85(1.27,2.69)
�60 2.37(1.62,3.47)
Duration of T2DM (in years)
�1 1
>1–5 1.22(0.80,1.87)
>5–10 1.68(1.09,2.58)
>10 2.50(1.64,3.80)
Length of hospital stay (in days)
�5 1
>5–10 2.44(1.87,3.18)
>10 3.00(2.25,4.00)
Blood glucose level (HbA1c)
<7% 1
�7% 2.10(1.68,2.62)
Unknown 1.18(0.68,2.04)
Neoplasms (C00-D48)
No 1
Yes 0.49(0.35,0.68)
Endocrine, nutritional and metabolic diseases (E00-E90)�
No 1
Yes 2.24(1.76,2.85)
Circulatory system diseases (I00-I99)
No 1
Yes 4.34(3.61,5.21)
Skin and subcutaneous tissue diseases (L00-L99)
No 1
Yes 1.63(1.03,2.57)
Musculoskeletal system and connective tissue diseases (M00-M99)
No 1
Yes 1.57(1.24,1.97)
Pregnancy, childbirth and the puerperium (O00-O99)
No 1
Yes 0.05(0.01,0.44)
�Excludes T2DM
Variables age, education, occupation, marital status, residence, health insurance, duration of T2DM, blood glucose
level (HbA1c), length of hospital stay, neoplasms, endocrine diseases, mental and behavioural disorders, nervous
system diseases, circulatory system diseases, respiratory system diseases, skin diseases, musculoskeletal system
diseases, genitourinary system diseases, pregnancy and the puerperium were included. (Sex, smoking, alcohol
drinking, infectious and parasitic diseases, blood diseases, digestive diseases were excluded.)
https://doi.org/10.1371/journal.pone.0220047.t004
Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0220047 July 17, 2019 10 / 16
patients in our study were prescribed β-Hydroxy β-methylglutaryl CoA (HMG CoA) reductase
inhibitors like atorvastatin, lovastatin and simvastatin. One of the severe adverse effects of stat-
ins is myopathy. These statins are metabolised by an enzyme, cytochrome P450 3A4
(CYP3A4). Calcium channel blockers like amlodipine are inhibitors of CYP3A4. When these
two drugs are administered simultaneously, for example, simvastatin plus amlodipine, amlodi-
pine can increase the level of simvastatin in plasma, which in turn can increase the risk of
myopathy [35,40]. Thus, there is an urgent need to develop, evaluate and implement interven-
tions to support medicines optimisation (and deprescribing) among T2DM patients.
The odds of polypharmacy prescription increased with patients’ age in our study, as in stud-
ies conducted among diabetes patients in Saudi Arabia and Brazil [16,18]. Even in studies con-
ducted among the general population in Switzerland and Japan, the prevalence of
polypharmacy increased with age [41,42]. Usually, older patients have more comorbidities and
seek care from multiple healthcare providers [43], which may increase the chance of polyphar-
macy. Even after we adjusted for some known comorbidities, age was found to be indepen-
dently associated with polypharmacy prescription. Due to the natural senescence process of
liver and kidneys in older patients, the risk of drug accumulation is more serious [44,45]. The
adverse effect of a drug can be misinterpreted as a sign or symptom of a new disorder and new
drugs may be added to the medication list to manage it, which is known as “prescription cas-
cade”. This further complicates the matter by increasing the risk of unwanted drug interactions
between existing and new drugs and resulting in adverse drug events, especially among older
patients who are already on multiple drugs [46].
The odds of polypharmacy prescription increased with the duration of T2DM in our study.
Similarly, a study conducted among T2DM patients in Italy reported that polypharmacy was
associated with�5 years duration of T2DM (1.93, 1.38–2.70) [17]. In another study conducted
among diabetes patients in Brazil, polypharmacy was found to be associated with�10 years
duration of T2DM (1.64, 1.36–1.98) [16]. With the progression of T2DM, the function and
mass of β-cells gradually decline [47]. In T2DM patients, single antidiabetic drugs like metfor-
min, sulfonylureas or thiazolidinediones cannot control their blood glucose levels for a long
period of time and as the disease progresses over time, they will need multiple antidiabetic
drugs [47]. In addition, the risk of vascular complications increases with the duration of
T2DM [48] and thus, will require multiple medicines as part of the management strategy.
We found that the odds of polypharmacy prescription increased with the length of hospital
stay in T2DM patients. Similarly, a study conducted among older patients in India reported
the association between longer length of hospital stay and polypharmacy (3.14, 2.09–4.71 for
10 to<15 days length of hospital stay; and 5.74, 2.43–13.51 for�15 days length of hospital
stay) [49]. Length of hospital stay is a known indicator of the severity of T2DM, its comorbidi-
ties and complications [50]. The more complex and severe the case is, the more medicines are
required to manage it.
The odds of polypharmacy prescription were higher in those with poor blood glucose level
in our study. In T2DM patients with poor blood glucose levels, additional antidiabetic drugs
are needed, as is evident from another study conducted among T2DM patients in the USA
[51]. It should be noted that poor blood glucose levels could be due to comorbidities (eg, other
metabolic disorders), requiring additional antidiabetic drugs. In our study, comorbidities were
adjusted for in the models.
We found that the average number of comorbidities was five among those who were pre-
scribed polypharmacy. The odds of polypharmacy prescription were higher in those with
comorbidities like other endocrine, nutritional and metabolic diseases (such as obesity, hyper-
uricaemia, hyperlipidaemia and T2DM micro-vascular complications), circulatory system dis-
eases (such as hypertension and T2DM macro-vascular complications like coronary heart
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disease and stroke), skin and subcutaneous tissue diseases, and musculoskeletal system and
connective tissue diseases. Similarly, in a study conducted among T2DM patients in Ireland,
those with one and�5 chronic illnesses were prescribed three and eight medicines on an aver-
age, respectively [52]. In another study conducted among T2DM in Italy, polypharmacy was
found to be associated with comorbidities, assessed using the Cumulative Illness Rating Scale
(CIRS) (1.9, 1.41–2.54 for CIRS�2) [17]. In a study conducted among diabetes patients in
Saudi Arabia, polypharmacy was found to be associated with cardiovascular diseases (2.89,
2.54–3.29), mental health conditions (2.19, 1.74–2.76), respiratory diseases (2.42, 1.92–3.03)
and musculoskeletal diseases (3.16, 2.31–4.30) [18]. Usually, T2DM patients will have at least
one comorbidity and approximately 40% of them will have�3 comorbidities [52,53]. It should
be noted that T2DM patients are also prone to skin diseases [54]. As mentioned above, there is
a high risk of “prescription cascade” in older patients, and itching is one of the known adverse
effects of drugs, which in turn will need medicines [55,56]. One of the prominent clinical
symptoms of the musculoskeletal system and connective tissue diseases is the pain, which will
also need medicines [57].
In this study, the odds of polypharmacy prescription were lower in those with comorbidi-
ties like neoplasms and during pregnancy, childbirth and the puerperium. The benign neo-
plasms do not require any medicine such as uterine leiomyoma, the pituitary tumour with no
function and hepatic haemangioma. We found that the odds of polypharmacy prescription
were lower in those with malignant neoplasms compared to no tumours (S1 Table). It should
be noted that patients with malignant neoplasms requiring multiple medicines are primarily
treated elsewhere (and not in this tertiary care department). Those admitted to this tertiary
care department usually have reduced life expectancy, and the primary management aim is to
provide palliative care with minimal medicines [27,34]. In fact, their blood glucose, blood pres-
sure and lipid targets are relaxed and thus, multiple medicines are avoided [27,34]. During
pregnancy, only insulin is approved for controlling blood glucose levels in China [27,34]. Simi-
larly, many medicines are not prescribed or used in pregnancy to avoid known and unknown
adverse effects on the foetus [58].
The study has a number of strengths and weaknesses. As far as we are aware, this was the
first study in China to explore polypharmacy prescription among T2DM patients. Our study
findings could be taken into consideration in future interventional studies aimed at supporting
medicines optimisation (and deprescribing) among these patients. This study was conducted
among T2DM patients who were discharged from the tertiary care department and thus, the
generalisability of study findings is limited to similar populations and settings. As mentioned
before, studies conducted in other diabetes (including T2DM) populations and settings have
reported a range of prevalence figures [15–21]. In China, studies conducted in community set-
tings have reported a much lower prevalence of polypharmacy (6–18%) [22–24]. Our study
focused on prescribed western medicines. Data on other important components such as over-
the-counter medicines, traditional Chinese medicines and actual usage of medicines were not
available in the database and needs further exploration to provide a more complete picture of
the issue. Missing data, which could lead to bias, were low in this study. A sample with missing
values for the variable was included in the regression analyses. This was a retrospective study,
which used an existing computerised medical records database. The primary purpose of the
development of this database was clinical and not research and thus, data quality issues (such
as accuracy and reliability) of routinely collected data cannot be ignored. However, hospital-
ised patients, due to disease severity, are usually precisely monitored, and this could have
improved the data quality. Recall error could have been a problem with self-reported data (eg,
duration of T2DM). The inaccurate measurement of the variable could mean that patients
were assigned to the wrong group, which resulted in an incorrect estimation of the association
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between duration of T2DM and polypharmacy prescription. There is a possibility that our
study findings were the outcome of other factors (such as cognitive performance, diet and
physical activity) not present in the database and so, not adjusted for in the models [16, 59–
61]. Similarly, only the current status of smoking and alcohol drinking was available in the
database and the past history was missing. Being a cross-sectional study, it was not possible to
assess the causal relationship between different variables and polypharmacy prescription. We
suggest conducting a longitudinal study among T2DM patients to evaluate the impact of vari-
ous factors (these as well as other potential factors) on polypharmacy prescription. In addition,
ours was a hospital-based study, and a population-based study might provide a different pic-
ture of the issue. The reasons could be different population characteristics, including their dis-
ease severity and healthcare-seeking behaviour.
In conclusion, around three fourth of T2DM patients at the tertiary care department were
prescribed polypharmacy, and the predictors were identified. The study findings could be
taken into consideration in future interventional studies aimed at supporting medicines opti-
misation (and deprescribing) among these patients.
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